Study Details
Ravulizumab: A Study Drug for Infants, Children, and Young Adults Ages 1 month to 18 years old with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT
(IRB#: IRB_00135225)
Thrombotic Microangiopathy (TMA) is blood clots that form in the body from damaged cells. Hematopoietic stem cell transplant (HSCT) is when other cells are used from a persons body to create normal blood cells. Ravulizumab is a study drug to help infants, children, and young adults ages 1 month to 18 years old with this disease after having HSCT. Research is needed to learn if the drug is safe and effective. The information we gain may aid patients.
- All genders
- Under 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Infants and children 1 month to 18 years old
- TMA diagnosis
- HSCT within the past 6 months at the time of participation
- Required vaccinations
- In-person at the University of Utah
Exclusion Criteria
- Bone marrow or stem cell transplant failure
- Mental health issue
- Participation in another study
- Pregnant or breastfeeding
- HIV
Will I be paid for my time?
Yes
IRB#: IRB_00135225
PI: AHMAD RAYES
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2022-02-09 07:00:00
Specialties: Pediatric Hematology & Oncology